HCPs 'don't differentiate well between cannabinoid-based meds and herbal cannabis'

7 July 2017

A consensus review has been published on the efficacy of cannabinoids as medical drugs and comparing them with other forms of cannabis treatments with herbal plants.

The aim of the article, written by a panel of experts and sponsored by Spain's leading drugmaker, Almirall (ALM: MC), is to review the most relevant scientific information available related to the medicinal use of different cannabinoids (natural or synthetic) for the treatment of human diseases, to reflect the present and also the potential medical utilities of cannabinoid based therapy.

Therapies covered include tetrahydrocannabinol (THC), cannabidiol (CBD) and a number of other cannabinoids, with the review entitled Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK